keyword
MENU ▼
Read by QxMD icon Read
search

Ulipristal acetate

keyword
https://www.readbyqxmd.com/read/28219738/ulipristal-acetate-administration-at-mid-cycle-changes-gene-expression-profiling-of-endometrial-biopsies-taken-during-the-receptive-period-of-the-human-menstrual-cycle
#1
Saúl Lira-Albarrán, Marta Durand, Marco F Larrea-Schiavon, Leticia González, David Barrera, Claudia Vega, Armando Gamboa-Domínguez, Claudia Rangel, Fernando Larrea
The aim of this study was to analyze the effects of mid-cycle administration of Ulipristal acetate (UPA) on gene expression in endometrial biopsies taken during the receptive phase of the cycle. Fourteen healthy menstruating women were studied during 14 control non-treated and 12 treated cycles with a single dose of 30 mg UPA when follicle diameter reached 20 mm. Ovulation in both treated and control cycles was confirmed by serial determinations of serum LH, progesterone and vaginal ultrasound. An endometrial biopsy at day LH+7, in each cycle, was taken for RNA microarray and qPCR analysis or prepared for histological and immunohistochemistry studies...
February 17, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28217674/uterine-fibroid-shrinkage-after-short-term-use-of-selective-progesterone-receptor-modulator-or-gonadotropin-releasing-hormone-agonist
#2
Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang
OBJECTIVE: The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women. METHODS: This retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging...
January 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28185997/rationale-and-design-of-asteroid-2-a-randomized-placebo-and-active-comparator-controlled-study-to-assess-the-efficacy-and-safety-of-vilaprisan-in-patients-with-uterine-fibroids
#3
Christian Seitz, Žana Bumbuliene, Ana Rosa Costa, Oskari Heikinheimo, Andrea Heweker, Robert Hudeček, Yves Jacquemyn, Gian Benedetto Melis, Pooja Parashar, Tomasz Rechberger, Antonio Cano Sánchez, Bart Van Aken, János Zatik, Kristina Gemzell-Danielsson
BACKGROUND: Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has received regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to 3months each, followed by a break to allow two menstruations to occur. We report the design of ASTEROID (Assess Safety and efficacy of vilaprisan in patients with uTERine fibrOIDs) 2, a phase 2 study examining the efficacy and safety of a novel PRM, vilaprisan, in women with UFs...
February 6, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/28169130/the-history-and-use-of-the-progesterone-receptor-modulator-ulipristal-acetate-for-heavy-menstrual-bleeding-with-uterine-fibroids
#4
REVIEW
Philippe Bouchard, Nathalie Chabbert-Buffet
Progesterone receptor modulators (PRM) or selective progesterone receptor modulators have two remarkable effects in treated women. They considerably suppress endometrial bleeding by incompletely understood mechanisms, and when administered in women with symptomatic fibroids, they produce a significant and potentially long-term decrease in fibroid volume. The crucial advantage of this therapy lies with the absence of suppression of ovarian oestrogen secretion, which is in contrast to GnRH agonists. Long-term treatments have proven to be useful, especially in women approaching the menopausal transition...
December 18, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28130434/selective-progesterone-receptor-modulator-sprm-ulipristal-acetate-upa-and-its-effects-on-the-human-endometrium
#5
L H R Whitaker, A A Murray, R Matthews, G Shaw, A R W Williams, P T K Saunders, H O D Critchley
STUDY QUESTION: What is the impact of administration of the selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA) on the endometrium of women with fibroids? SUMMARY ANSWER: UPA administration altered expression of sex-steroid receptors and progesterone-regulated genes and was associated with low levels of glandular and stromal cell proliferation. WHAT IS KNOWN ALREADY: Administration of all SPRM class members results in PAEC (progesterone receptor modulator associated endometrial changes)...
January 26, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28126541/temporary-removal-pharmacokinetics-of-levonorgestrel-and-ulipristal-acetate-emergency-contraception-in-women-with-normal-and-obese-body-mass-index
#6
Piyapa Praditpan, Angie Hamouie, Cale N Basaraba, Renu Nandakumar, Serge Cremers, Anne R Davis, Carolyn L Westhoff
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
January 23, 2017: Contraception
https://www.readbyqxmd.com/read/27990057/ulipristal-acetate-for-fibroids
#7
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Australian Prescriber
https://www.readbyqxmd.com/read/27990056/ulipristal-acetate-for-emergency-contraception
#8
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Australian Prescriber
https://www.readbyqxmd.com/read/27970726/cost-utility-analysis-of-ulipristal-acetate-5-mg-for-long-term-treatment-of-moderate-to-severe-symptoms-of-uterine-fibroids-in-portugal
#9
A Paquete, M Lehmann, D P Silva, C G Pinto
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970716/budget-impact-of-ulipristal-acetate-5mg-in-pre-operative-treatment-of-uterine-fibroids-an-analysis-based-on-public-data-on-hospital-stays-in-france
#10
M Trancart, M Lehmann, A Lafuma
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27918164/-the-possibility-of-using-progesterone-receptor-modulators-in-the-treatment-of-myomas
#11
O Šimetka, J Klát, S Bajsová
OBJECTIVE: To summarize the knowledge about the effect of selective progesterone receptor modulators and their use in the treatment of myomas in women of childbearing age and in perimenopause. DESIGN: Review article. RESULTS: Long-term treatment with ulipristal acetate maximizes its effectiveness, it helps to achieve faster bleeding control and increases the number of pa-tients with fibroid volume reduction of more than 50%. Ulipristal acetate is the most effective drug in the medical treatment of myomas and its use will change the approach to surgical treatment...
2016: Ceská Gynekologie
https://www.readbyqxmd.com/read/27914766/histomorphological-changes-in-endometriosis-in-a-patient-treated-with-ulipristal-a-case-report
#12
J Bateman, O Bougie, S Singh, S Islam
BACKGROUND: Selective progesterone receptor modulators have shown efficacy in the treatment of endometriosis, however they are not currently licensed in Canada for this purpose. Their histomorphological effects have been well documented in the endometrium, but not in endometriosis. CASE REPORT: The patient presented with uterine fibroids and heavy menstrual bleeding, and was treated with ulipristal acetate over three 90-day courses. She eventually elected to undergo definitive surgical management...
January 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/27898340/real-world-data-of-1473-patients-treated-with-ulipristal-acetate-for-uterine-fibroids-premya-study-results
#13
Hervé Fernandez, Torsten Schmidt, Martin Powell, Ana Patrícia Freitas Costa, Pablo Arriagada, Christian Thaler
OBJECTIVES: To characterize and describe treatment with Ulipristal acetate (UPA) in a pre-operative setting and to evaluate the safety, effectiveness, and Health Related Quality of Life (HRQoL) outcomes in a population treated according to standard clinical practice in the EU. STUDY DESIGN: Multi-centre, prospective, non-interventional study (PREMYA) of patients diagnosed with moderate to severe symptoms of uterine fibroids and undergoing a pre-operative treatment with UPA (Esmya(®)) at 73 clinical practice sites within the EU...
January 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27896473/experience-with-oral-emergency-contraception-since-the-otc-switch-in-germany
#14
Marion Kiechle, Miriam Neuenfeldt
PURPOSE: In March 2015, the oral emergency contraceptives levonorgestrel (LNG) and ulipristal acetate (UPA) were released from prescription-only status in Germany. The main research question is to analyse whether the OTC status of oral emergency contraceptives has an influence on the patterns of use. METHODS: All information is based on searches for public domain sources on emergency contraception. Searches were made for scientific publications, statistics, and surveys...
November 28, 2016: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/27889055/medical-or-surgical-management-of-fibroids-an-internet-survey-of-gynecologists-views
#15
Elisa Pazzaglia, Julie Praet, Jean Vandromme, Serge Rozenberg
AIM: To assess the attitudes of gynecologists toward symptomatic fibroids and analyze which factors influence their choice of treatment. MATERIAL AND METHOD: We surveyed the attitude of Belgian gynecologists toward patients' cases. We used a vignette of a woman with symptomatic fibroids and modified 3 factors: her age, her parity and her desire for pregnancy, thereby establishing 12 different cases. We ensured that each gynecologist (n=1437) received one case, chosen randomly, by email...
January 2017: Maturitas
https://www.readbyqxmd.com/read/27882756/-the-use-of-selective-progesterone-receptor-modulators-in-the-treatment-of-myomas
#16
O Šimetka, J Klát
OBJECTIVE: To summarize the knowledge of the effect of selective progesterone receptor modulators and their use in the treatment of myomas in women of childbearing age and in perimenopause. DESIGN: Review articleResults: Long-term treatment with ulipristal acetate maximizes its effectiveness, it helps to achieve faster bleeding control and increases the number of patients with fibroid volume reduction of more than 50%. Ulipristal acetate is the most effective drug in the medical treatment of myomas and its use will change the approach to surgical treatment...
2016: Ceská Gynekologie
https://www.readbyqxmd.com/read/27786570/ulipristal-acetate-for-pre-operative-treatment-of-moderate-to-severe-uterine-fibroids-in-women-of-reproductive-age-in-the-netherlands-cost-minimization-analysis-and-budget-impact-analysis
#17
N Zakiyah, A D I van Asselt, M J Postma
OBJECTIVE: Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands. The analysis was performed and applied within the framework of the ulipristal acetate submission for reimbursement in 2012...
March 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/27785169/non-prescription-dispensing-of-emergency-oral-contraceptives-recommendations-from-the-german-federal-chamber-of-pharmacists-bundesapothekerkammer
#18
Martin Schulz, Ralf Goebel, Claudia Schumann, Petra Zagermann-Muncke
BACKGROUND: Emergency hormonal contraceptives (EHC) are contraceptives used to prevent unintended pregnancy following unprotected sexual intercourse (USI) or contraceptive failure. The EHCs available without a prescription include medicines containing levonorgestrel (LNG) in more than 80 countries and, recently, based on an EU-switch ellaOne®, which contains ulipristal acetate (UPA). EHCs work by stopping or delaying ovulation. Those containing LNG can be used up to 72 hours after USI or contraceptive failure, while UPA can be used up to 120 hours...
July 2016: Pharmacy Practice
https://www.readbyqxmd.com/read/27769767/-i-don-t-know-what-i-would-have-done-women-s-experiences-acquiring-ulipristal-acetate-emergency-contraception-online-from-2011-to-2015
#19
Nicole K Smith, Kelly Cleland, Brandon Wagner, James Trussell
OBJECTIVES: This study describes women's reasons for seeking ulipristal acetate (UPA) for emergency contraception (EC) through the only authorized online retailer for UPA EC in the US. STUDY DESIGN: Women aged 14 to 59 years, living in states that allow prescription medications to be shipped from out-of-state, accessed the KwikMed online pharmacy between January 2011 and December 2015. After completing a medical eligibility screener, women answered optional multiple-choice questions...
October 18, 2016: Contraception
https://www.readbyqxmd.com/read/27740868/safety-of-treatment-of-uterine-fibroids-with-the-selective-progesterone-receptor-modulator-ulipristal-acetate
#20
Jacques Donnez, Olivier Donnez, Marie-Madeleine Dolmans
During the last decade, there has been increased emphasis on the role of progesterone in the promotion of fibroid growth, as well as heightened interest in modulating progesterone pathways by use of selective progesterone receptor modulators (SPRMs). Among them, ulipristal acetate (UPA) has proved its efficacy in the management of symptomatic myomas by controlling bleeding and inducing amenorrhea, and reducing the size of myomas in the majority of cases. Areas covered: In this review, we summarize published scientific studies exploring evidence of the safety of SPRMs and particularly UPA, a drug approved for the management of symptomatic uterine fibroids...
December 2016: Expert Opinion on Drug Safety
keyword
keyword
119605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"